Close Menu

NEW YORK (360Dx) – A point-of-care diagnostic test that could determine within minutes whether a patient has been infected with the bacterium that causes anthrax is moving forward in research and development with the support of the US Department of Health and Human Services.

Under a three-year, $8.1 million contract, the HHS Biomedical Advanced Research and Development Authority (BARDA) will work with Seattle, Washington-based InBios International to develop a diagnostic test and conduct studies needed to apply for clearances with the US Food and Drug Administration.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.